Mitigating lead exposure effects through maternal care and enriched environments

Phar­ma com­pa­nies are ex­press­ing fears that the FDA’s new ad­vanced man­u­fac­tur­ing tech des­ig­na­tion guid­ance could “bur­den” the agency, ac­cord­ing to com­ments re­cent­ly made pub­lic. The

Har­mo­ny Bio­sciences is pay­ing $60 mil­lion in cash to get its hands on Zyner­ba Phar­ma­ceu­ti­cals and a ther­a­py it’s de­vel­op­ing to treat two rare dis­eases.